146 related articles for article (PubMed ID: 23221082)
1. A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport.
Kazmi N; Hossain MA; Phillips RM
IEEE/ACM Trans Comput Biol Bioinform; 2012; 9(6):1595-606. PubMed ID: 23221082
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
3. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
Hicks KO; Siim BG; Pruijn FB; Wilson WR
Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
[TBL] [Abstract][Full Text] [Related]
4. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
Hicks KO; Pruijn FB; Sturman JR; Denny WA; Wilson WR
Cancer Res; 2003 Sep; 63(18):5970-7. PubMed ID: 14522924
[TBL] [Abstract][Full Text] [Related]
5. Avascular tumour growth dynamics and the constraints of protein binding for drug transportation.
Kazmi N; Hossain MA; Phillips RM; Al-Mamun MA; Bass R
J Theor Biol; 2012 Nov; 313():142-52. PubMed ID: 22974970
[TBL] [Abstract][Full Text] [Related]
6. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
Hicks KO; Pruijn FB; Secomb TW; Hay MP; Hsu R; Brown JM; Denny WA; Dewhirst MW; Wilson WR
J Natl Cancer Inst; 2006 Aug; 98(16):1118-28. PubMed ID: 16912264
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
Hay MP; Hicks KO; Pruijn FB; Pchalek K; Siim BG; Wilson WR; Denny WA
J Med Chem; 2007 Dec; 50(25):6392-404. PubMed ID: 18001018
[TBL] [Abstract][Full Text] [Related]
8. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
Hicks KO; Fleming Y; Siim BG; Koch CJ; Wilson WR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):641-9. PubMed ID: 9806526
[TBL] [Abstract][Full Text] [Related]
9. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
11. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
Hay MP; Pchalek K; Pruijn FB; Hicks KO; Siim BG; Anderson RF; Shinde SS; Phillips V; Denny WA; Wilson WR
J Med Chem; 2007 Dec; 50(26):6654-64. PubMed ID: 18052317
[TBL] [Abstract][Full Text] [Related]
13. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Siim BG; Menke DR; Dorie MJ; Brown JM
Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
[TBL] [Abstract][Full Text] [Related]
14. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
15. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Yang B; Reynolds CP
Clin Cancer Res; 2005 Apr; 11(7):2774-80. PubMed ID: 15814660
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
Nakashima H; Uto Y; Nakata E; Nagasawa H; Ikkyu K; Hiraoka N; Nakashima K; Sasaki Y; Sugimoto H; Shiro Y; Hashimoto T; Okamoto Y; Asakawa Y; Hori H
Bioorg Med Chem; 2008 Sep; 16(18):8661-9. PubMed ID: 18715787
[TBL] [Abstract][Full Text] [Related]
17. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluctuating oxygenation on tirapazamine efficacy: Theoretical predictions.
Cárdenas-Navia LI; Secomb TW; Dewhirst MW
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):581-6. PubMed ID: 17236974
[TBL] [Abstract][Full Text] [Related]
19. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
Pruijn FB; Sturman JR; Liyanage HD; Hicks KO; Hay MP; Wilson WR
J Med Chem; 2005 Feb; 48(4):1079-87. PubMed ID: 15715475
[TBL] [Abstract][Full Text] [Related]
20. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
Kyle AH; Minchinton AI
Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
